Comparative Pharmacology
Head-to-head clinical analysis: EXELON versus RIVASTIGMINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELON versus RIVASTIGMINE TARTRATE.
EXELON vs RIVASTIGMINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Reversible, non-competitive inhibitor of acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine concentration in the CNS.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
Initial 1.5 mg orally twice daily; increase by 1.5 mg twice daily at ≥2-week intervals to maximum 6 mg twice daily if tolerated.
None Documented
None Documented
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
The terminal elimination half-life is approximately 1.5 hours after oral administration. However, due to slow dissociation from the cholinesterase enzyme, the pharmacodynamic half-life (duration of enzyme inhibition) is about 10 hours, supporting twice-daily dosing.
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Rivastigmine is extensively metabolized by cholinesterase-mediated hydrolysis to the inactive decarbamylated metabolite, NAP226-90, which is then excreted renally. Approximately 97% of a dose is excreted in urine as metabolites (<1% as parent drug), and about 0.4% in feces. Renal elimination accounts for >90% of total clearance.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor